Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP404705.RAqOgdf3Bv2c_M7pRQwhpppDoPTVheY7weORqg_CBFrNI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP404705.RAqOgdf3Bv2c_M7pRQwhpppDoPTVheY7weORqg_CBFrNI130_assertion type Assertion NP404705.RAqOgdf3Bv2c_M7pRQwhpppDoPTVheY7weORqg_CBFrNI130_head.
- NP404705.RAqOgdf3Bv2c_M7pRQwhpppDoPTVheY7weORqg_CBFrNI130_assertion wasGeneratedBy ECO_0000203 NP404705.RAqOgdf3Bv2c_M7pRQwhpppDoPTVheY7weORqg_CBFrNI130_provenance.
- NP404705.RAqOgdf3Bv2c_M7pRQwhpppDoPTVheY7weORqg_CBFrNI130_assertion wasDerivedFrom befree-20140225 NP404705.RAqOgdf3Bv2c_M7pRQwhpppDoPTVheY7weORqg_CBFrNI130_provenance.
- NP404705.RAqOgdf3Bv2c_M7pRQwhpppDoPTVheY7weORqg_CBFrNI130_assertion SIO_000772 18930989 NP404705.RAqOgdf3Bv2c_M7pRQwhpppDoPTVheY7weORqg_CBFrNI130_provenance.
- NP404705.RAqOgdf3Bv2c_M7pRQwhpppDoPTVheY7weORqg_CBFrNI130_assertion evidence source_evidence_literature NP404705.RAqOgdf3Bv2c_M7pRQwhpppDoPTVheY7weORqg_CBFrNI130_provenance.
- NP404705.RAqOgdf3Bv2c_M7pRQwhpppDoPTVheY7weORqg_CBFrNI130_assertion description "[A total of 91 patients with RA (89% female; 76.7% rheumatoid factor (RF) positive) starting therapy with infliximab were evaluated at 0, 6 and 30 weeks using the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) response criteria and the 28-joint Disease Activity Score (DAS28) was evaluated using three parameters, including C-reactive protein (CRP) (DAS28 3v-CRP) changes during the follow-up.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP404705.RAqOgdf3Bv2c_M7pRQwhpppDoPTVheY7weORqg_CBFrNI130_provenance.